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Antiviral therapyThe new H1N1 swine-origin inﬂuenza virus (S-OIV) strain is a global health problem. The elucidation of the
virus–host relationship is crucial for the control of the new infection. Two human monoclonal antibody Fab
fragments (HMab) neutralizing the novel H1N1 inﬂuenza strain at very low concentrations were cloned
before the emergence of S-OIV from a patient who had a broad-range H1N1 serum neutralizing activity. The
two HMabs neutralized all tested H1N1 strains, including S-OIV and a swine strain with IC50 ranging from 2
to 7 μg/ml. Data demonstrate that infection with previously circulating H1N1 strains can elicit antibodies
neutralizing S-OIV. Finally, the human genes coding for the neutralizing HMabs could be used for generating
full human monoclonal IgGs that can be safely administered being potentially useful in the prophylaxis and
the treatment of this human infection.ork.
ll rights reserved.© 2009 Elsevier Inc. All rights reserved.Introduction
Recently, a new strain of human H1N1 inﬂuenza A virus (swine-
origin inﬂuenza virus; S-OIV) was identiﬁed (Fraser et al., 2009a). As
of September 11th, 2009, the virus has spread to many countries with
more than 277,607 cases and 3205 deaths. These ﬁgures, together
with the fact that the new virus has been assessed as having pandemic
potential, make this new infection a serious concern for the global
health(Fraser et al., 2009b; Trifonov et al., 2009b). The elucidation of
the interplay between the new inﬂuenza virus and the human host,
mainly the identiﬁcation of S-OIV antigenic regions that are able to
elicit broad-range and neutralizing antibodies, is crucial for the
understanding of the epidemiology of this disease.
Indeed, human monoclonal antibodies with broad-range neutral-
izing activity against S-OIV can be key reagents in this scenario, as
they can be used to probe in vitro the vaccine candidates and
providing useful information for understanding data generated by
preliminary in vivo studies(Parren et al., 1996). Furthermore, human
monoclonal antibodies neutralizing inﬂuenza viruses are molecules
potentially useful in prophylaxis and therapy (Simmons et al., 2007;
Trifonov et al., 2009b). Even if antibody-based prophylaxis andtherapy of inﬂuenza is at present an unexplored option, polyclonal
and monoclonal human antibodies are effectively used in a number of
different viral infections (Sawyer, 2000). It has been demonstrated
that anti-inﬂuenza mouse and human monoclonal antibodies are
effective in prophylaxis and therapy in mice (Palladino et al., 1995;
Renegar et al., 2004; Smirnov et al., 2000), and passive immunization
by vertical transmission of anti-inﬂuenza antibodies is protective
against infection both in animal models and in human subjects (Luke
et al., 2006; Martinez, Tsibane, and Basler, 2009; Prabakaran et al.,
2009; Prabhu et al., 2009; Puck et al., 1980; Reuman et al., 1983;
Simmons et al., 2007; Sui et al., 2009; Sun et al., 2009; Sweet et al.,
1987a, 1987b; Throsby et al., 2008; Yoshida et al., 2009; Yu et al.,
2008). All these observations indicate that passive antibody adminis-
tration could be a potentially useful adjunctive treatment and
preventive option in the S-OIV infection.
In this paper, we describe the molecular cloning, the binding
characteristics, and the broad-range neutralizing activity of two
human monoclonal antibody Fab fragments (HMab) directed against
S-OIV hemagglutinin (S-HA). These antibodies, cloned from a patient
before the emergence of the S-OIV strain, demonstrate that exposure
to previous H1N1 strains elicits the production of S-OIV-neutralizing
antibodies. The data presented here document not only that previous
inﬂuenza H1N1 infections can provide a certain degree of protection,
but also that some epidemiological features of the S-OIV infection as
well as some unexplained results of the preliminary in vivo vaccine
trials can be clariﬁed at the molecular level.
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Two distinct HMabs, named PN-SIA28 and PN-SIA49, were cloned
from a patient exposed to previously circulating H1N1 inﬂuenza A
strains, with a negative clinical history for inﬂuenza infection in the
last years and with a detectable serum neutralizing activity against a
1934 inﬂuenza A isolate.Fig. 1. Immunoﬂuorescence on A/Milan/UHSR1/2009-infected MDCK cells or HA-transfecte
(b, c [100 magniﬁcation]), mouse anti-NP1 (d), the negative control Fab509 (e) and a doub
transfected with recombinant A/Puerto Rico/8/1934 HA expression vector and stained with
HEK293T cells transfected with recombinant A/Milan/UHSR1/2009 (S-OIV) HA expression v
(m) and PN-SIA49 (n). HEK293T cells transfected with recombinant A/South Carolina/1/18
HMabs PN-SIA28 (p) and PN-SIA49 (q). Mock-transfected HEK293T cells stained with contWhen tested in immunoﬂuorescence assay, both Mabs recognized
cells infected with the S-OIV strain (A/Milan/UHSR1/2009), with the
human strains A/Puerto Rico/8/34 (A/PR/8/34); A/Wilson-Smith/33
(A/WS/33); A/Malaya/302/54 (A/Mal/302/54); A/New Caledonia/
20/99 (A/NC/20/99), and with a swine strain (A/swine/Parma/1/
97). No reactivity was demonstrated against the A/Victoria/3/75
H3N2 nor against the B/Lee/40 inﬂuenza B strain. Ind cells. MDCK cells stained after 8 h of infection with HMabs PN-SIA28 (a) and PN-SIA49
le stain with HMabs PN-SIA28 and PN-SIA49 of mock infected cells (f). HEK293T cells
positive control M145 Monoclonal antibody (g) HMabs PN-SIA28 (h) and PN-SIA49 (i).
ector and stained with positive control M145Monoclonal antibody (l), HMabs PN-SIA28
HA expression vector and stained with positive control M145 Monoclonal antibody (o),
rol M145 monoclonal antibody (r). HMabs PN-SIA28 (s) and PN-SIA49 (t).
Fig. 2.Western blot on transfected cell lysates. Western blot on lysates of HEK293T cells
transfectedwith A/Milan/UHSR1/2009 (S-OIV) HA expression vector (lanes a–d and h)
or onmock-transfected cells (lanes e and g). Lanes: (a) positive serumdiluted 1:500; (b)
positive serum diluted 1:1000; (c) PN-SIA28; (d) PN-SIA49; (e) PN-SIA28 (on mock
lysate); (f) MagicMark XP (Invitrogen); (g) PN-SIA49 (on mock lysate); (h) anti-H1
positive control Anti-H1(GeneTex).
Table 1
IC50 values against H1N1 strains tested in this study (rounded to the ﬁrst decimal).
PN-SIA28 IC50 PN-SIA49 IC50
A/PR/8/34 4.1 μg/ml 2.1 μg/ml
A/WS/33 2.9 μg/ml 4.5 μg/ml
A/Mal/302/54 3.4 μg/ml 2.7 μg/ml
A/NC/20/99 7.0 μg/ml 6.9 μg/ml
A/swine/Parma/1/97 3.9 μg/ml 2.3 μg/ml
A/Milan/UHSR1/2009 (S-OIV) 4.0 μg/ml 2.8 μg/ml
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clear cytoplasmic pattern with plasma membrane reinforcement (Fig.
1) against S-OIV and all tested inﬂuenza A strains. No differences were
observed among cells infectedwith the different isolates. Notably, cells
transfected with the recombinant hemagglutinin (HA) genes of A/
Puerto Rico/8/1934, A/Milan/UHSR1/2009 and A/South Carolina/1/
18 were recognized by both HMab (Fig. 1), thus suggesting that both
PN-SIA28 and PN-SIA49 bind to extremely conserved antigenic
epitopes that are present in all H1 HAs we analyzed.
The epitope recognized by both antibodies is conformational as
evaluated by Western blot analysis and present only in the HA0 form
of hemagglutinin. In fact, no binding was observed under denaturing
conditions and nor HA1 or HA2 subunits were separately recognized
by PN-SIA28 and PN-SIA49 (Fig. 2).
PN-SIA28 and PN-SIA49 showed a strong neutralization activity
against S-OIV and all other H1N1 strains used in the study. When
neutralization activity was evaluated with immunoﬂuorescence
reduction assay PN-SIA49 featured IC50 (Fab concentration giving
50% of neutralization) ranging from 2.1 μg/mL against A/H1N1/PR/8/
34 to 6.9 μg/mL against A/NC/20/99. PN-SIA49 neutralized S-OIV
strain (A/Milan/UHSR1/2009) with an IC50 of 2.8 μg/mL. PN-SIA28
was demonstrated to have an IC50 ranging from 3.0 μg/mL against A/
H1N1/WS/33 to 7.0 μg/mL against A/H1N1/NC/20/99. PN-SIA28
neutralized S-OIV strain with an IC50 of 4.0 μg/mL. No neutralizing
activity was demonstrated for both Mabs against the B/Lee/40
inﬂuenza B strain nor against A/Victoria/3/75 H3N2 strain. (Table 1,
Fig. 3). Similar results were obtained with plaque reduction assay
(Fig. 4). When both Mabs were tested against H5N1 inﬂuenza viruses,
no reductions of EID50 values were observed comparedwith untreated
viral inoculums (A/turkey/Turkey/1/2005: negative control: 107.5
EID50/100μl, PN-SIA28: 106.83 EID50/100μl, PN-SIA49: 107 EID50/100μl;
A/chicken/Egypt/A6/2008: negative control: 106.24 EID50/100μl,
PN-SIA28: 106.7 EID50/100μl, PN-SIA49: 107.2 EID50/100μl). DNA
sequence of the light and heavy variable regions demonstrated that
the two Hmabs are different. Genbank accession numbers of the
heavy and light sequences of PN-SIA28 and PN-SIA49 areFig. 3. Fluorescence inhibition assay. Sigmoidal dose–response curve ﬁt nonlinear regression
paper. IC50 values for H1N1 strains are reported for in Tab I. A control unrelated Fab e509 wGQ867592 and GQ867595; GQ867593 and GQ867594, respectively.
PN-SIA28 and PN-SIA49 VH genes were V3-30 and V3-23,
respectively. Both antibodies were mutated with respect to the
germline encoded VH gene sequences (94.62% and 92.36% identity,
respectively) (Fig. 5).
Discussion
Pandemic inﬂuenza viruses have emerged at least three times in
the last 100 years with the most severe being the 1918 H1N1 Spanish
inﬂuenza. The risk of an inﬂuenza pandemic caused by the newly
emerged S-OIV strain is real, and the consequences of this event are
difﬁcult to estimate but could be catastrophic. Even if the pathogenic
potential of the novel strains appears lower than that of the 1918H1N1
Inﬂuenza virus, the possibility of a further evolution of the pathogen
cannot be excluded (Lipsitch et al., 2009). The understanding of the
role played by immunity elicited by previously circulating viruses, a
better knowledge of the virus–host interplay, and more importantly,
the availability of adjunctive novel tools for preventing and treating
this disease may be crucial in contrasting a possible pandemic.
The molecular cloning of from an unexposed patient of human
monoclonal antibodies, endowed with strong neutralizing activity
against S-OIV and against a broad range of human and swine H1N1
isolates, is the clear demonstration that some conserved antigenic
determinants present in a wide range of H1N1 viruses are also present
in the S-OIV strain. The two Mabs are displaced in competition
experiments by the mouse Mab C179 (Takara), and they compete the
one with the other (data not shown). This indicates that the two
epitopes recognized by the two HMabs described in this paper are at
least overlapping and situated in the stem region of the HA molecule.
The presence of antibodies neutralizing a wide range of H1N1
inﬂuenza isolates (including S-OIV) in the antibody repertoire elicited
by infection with previously circulating strains can explain the milder
clinical syndrome and the lower rate of this infection observed in
older subjects (Trifonov et al., 2009a, 2009b). Itoh et al. (2009) have
shown that only sera of those born before 1918 have some
neutralizing activity against S-OIV, suggesting a close serological
relation between the novel strain with the 1918 pandemic strain but
not with the antigenically divergent human H1N1 viruses circulating
in the 1920s to 1950s and since 1977. This is apparently in contrast
with our observation, as our antibodies are derived from the
repertoire of a patient born well after 1918. However, neutralization
assays performed with polyclonal sera cannot fully dissect the
humoral immune response and it is likely that only the minority of
antibodies elicited after the infection is endowed with cross-
neutralizing activity, being the majority directed against more
antigenic and variable viral antigens.
Furthermore, recently published data on the preliminary vaccine
trials (Galli et al., 2009; Hancock et al., 2009) noted an unanticipated
robust immune response to the H1N1 vaccine after a single dose
administration even in patients with no measurable antibodies
against S-OIV at the baseline. This unexpected brisk response to the
vaccination can be explained by an immunotypic similarity not yet
recognized between the 2009 H1N1 virus and recent seasonal strains.
The data presented in this paper are providing a molecular evidence
supporting this hypothesis, being important in the current time-
limited run for the quest of an effective vaccination strategy and
schedule.
Finally, these HMabs have the potential of being useful as
adjunctive tools in treatment and prophylaxis in the unfortunate
case of a S-OIV pandemic. In a mouse model of H5N1 inﬂuenza
infection, neutralizing human monoclonal antibodies were proven tois reported for PN-SIA28 and PN-SIA49 (red line) against all viral strains studied in this
as also used (black line).
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Fig. 4. Plaque inhibition assay. Sigmoidal dose–response curve ﬁt nonlinear regression is reported for PN-SIA28 and PN-SIA49 against all viral strains studied in this paper.
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Fig. 5. Sequence analysis of VH genes of PN-SIA28 and FN-SIA HMabs. Alignment of VH sequences (nucleotides and amino acids) with each germline IGHV gene was performed using
the International ImMunoGeneTics database. The CDR3 gene segments are underlined.
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causing a milder disease and strongly reducing virus dissemination
(Simmons et al., 2007). Therapy and prophylaxis of S-OIV infection by
administration of human monoclonal antibodies is a plausible
strategy. Several reports related to the 1918 “Spanish” pandemic
indicated as early treatment with blood product from recovered
patients was associated with a strong reduction in mortality, which
was more evident in the case of a early treatment (Luke et al., 2006),
with the speculation that the administration of neutralizing anti-
bodies present in the blood-derived products favorably modiﬁed the
virus–host balance causing a milder disease and preventing the
development of respiratory complications (Luke et al., 2006).
Administration of human monoclonal antibodies neutralizing S-OIV
has the potential of having the same effect. The IC50 values of PN-
SIA28 and PN-SIA49 Fabs are in the micromolar range (2.1–7.0 μg/
ml), comparable to those described previously by Throsby et al. (IC50
ranging from 0.55 to 15 μg/ml) (Throsby et al., 2008) or remarkably
lower than those described by Sui (IC50 in the order of 10 μg/ml) (Sui
et al., 2009). It should be noted that both works described the
neutralizing activities of recombinant full IgGs while our HMabs are in
the Fab form, and usually the neutralization capacity of Fabs strongly
increases once expressed in IgG form (Lamarre and Talbot, 1995).
Finally, even if most of the currently circulating S-OIV strains are
sensitive to mono-therapy with Oseltamivir and Zanamivir, in the
absence of additional drugs they will probably give rise to resistant
strains, as recently observed in these pandemics in Denmark, Japan,
and Hong Kong (http://www.who.int/csr/disease/swineﬂu/notes/
h1n1_antiviral_resistance_20090708/en/index.html) and as already
happened with the vast majority of seasonal H1N1 that have now
become resistant (Shetty, 2009). In the current situation, not knowing
in advance the efﬁcacy and of an anti-S-OIV vaccine, having an
alternative path open to the scientiﬁc community could be important.Humanmonoclonal antibodymass production is feasible, scalable, the
ﬁnal product is free of adventitious agents and it is utilizing well-
known procedures that are used formany drugs. Finally, given the fact
that these antibodies are of human origin, the risk of unwanted effects
is minimal.
In summary, the human monoclonal antibodies neutralizing the
pandemic H1N1 S-OIV strain can be useful tools for the understanding
of the disease, for the understanding of vaccine trial data in the
shortest possible time, and can constitute the basis, alone or in a
combination with other monoclonal antibodies, for a new class of
drugs to be used in the treatment and in the prophylaxis of this disease.
Materials and methods
This work was approved by the San Raffaele ethical committee,
and all human samples were collected after informed consent was
obtained.
Human monoclonal antibodies
A patient, of the age of 55, with a negative clinical history of
infection with inﬂuenza virus in the past 10 years, and with a serum
neutralizing titer (IC50N1:20) against a reference H1N1 1934 strain
(A/PR/8/34), was used as a source of lymphocytes 3 weeks after a
routine inﬂuenza seasonal vaccination and after written informed
consent was given. This procedure was performed well before the
emergence of the novel S-OIV strain. Fifteen B-cell lines producing
antibodies reacting in immunoﬂuorescence with inﬂuenza A-infected
cells were obtained by Epstein-Barr Virus (EBV) transformation (Cole
et al., 1984), and subsequently cDNA coding for Fab fragments were
PCR ampliﬁed and cloned in appropriate bacterial expression vector
(Burioni et al., 1997, 1998a) for avoiding instability of antibody
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Transformed bacteria were used for production of the recombinant
Fabs (Burioni et al., 1994; Perotti et al., 2008), which were puriﬁed as
previously described (Burioni et al., 1998b). Only two of the Fabswere
demonstrated to be endowed with neutralizing activity. An anti-
hepatitis C virus Fab, named e509 (Burioni et al., 1998b), produced
and puriﬁed with an identical procedure, was used as a negative
control in all experiments. Mutations identiﬁed by comparing each
sequence with germline sequences (International ImMunoGeneTics
database at http://imgt cines.fr/) were deﬁned on the basis of
nucleotide changes in the VH segment.
Isolation and identiﬁcation of inﬂuenza A/Milan/UHSR1/2009 strain
All experiments were conducted in the BLS3 laboratory of the
Università Vita-Salute San Raffaele. The swine origin inﬂuenza virus
(S-OIV) used in this study was isolated from the pharyngeal swab of a
26-year-old Italian patient of our hospital referring fever and malaise
after a recent travel to the United States. The swab was seeded on 80%
conﬂuent MDCK (Madin-Darby canine kidney) cells (ATCC no. CCL-
34TM). The cells were infected in modiﬁed Eagle medium (MEM,
GIBCO) with the addition of 2 μg/ml of trypsin. After 1 h, 10% fetal
bovine serum (GIBCO), 50 μg/ml of penicillin (GIBCO), 100 μg/ml of
streptomycin (GIBCO) and of L-glutamine (2 mM) (EuroClone) were
added and cells were incubated at 35 °C, in 5% CO2 atmosphere for 5
days. Identiﬁcation was performed directly on patient's swab sample
and on culture supernatant by whole length ampliﬁcation and
sequencing of the S-HA gene by using a previously described RT-
PCR protocol (Puthavathana et al., 2005) with minor modiﬁcations
(Baek et al., 2009). Primer forward was Bm-HA-1-Fw 5′-TAT TCG TCT
CAG GGA GCA AAA GCA GGG G-3′, primer reverse was Bm-NS-890-
Rev 5′-ATA TCG TCT CGT ATT AGT AGA AAC AAG GGT GTT T-3′. The
reaction was performed using the SuperScript III One-Step RT-PCR
System with Platinum® Taq High Fidelity (Invitrogen) and the
following thermal proﬁle: 30 min 50 °C; 10 min 94 °C; 30 s 94 °C,
1 min 53 °C, 1 min 72 °C (45 cycles). Sequencing was performed by
using BigDye Terminators 3.1 with the automatic sequencer AbiPr-
ism3130 (Applied Biosystems); the primers used in the ampliﬁcation
are: F1 5′-TAG GAA ACC CAG AAT GCG-3′, F2 5′-TAC TGG ACC TTG CTA
GAA-3′, F3 5′-TCT ATT TGG AGC CAT TGC-3′.
Other inﬂuenza strains of human, swine or animal origin used in
this study
The following reference strains were used: A/Puerto Rico/8/34
(A/PR/8/34); A/Wilson-Smith/33 (A/WS/33); A/Malaya/302/54
(A/Mal/302/54); A/New Caledonia/20/99 (A/NC/20/99). A swine
strain (A/swine/Parma/1/97) was kindly provided by the Istituto
Zooproﬁlattico di Brescia, Brescia, Italy. The inﬂuenza B strain B/Lee/
40 and the inﬂuenza A/Victoria/3/75 were also tested in all studies.
The avian A/chicken/Egypt/A6/2008 and A/turkey/Turkey/1/2005
inﬂuenza A (H5N1) strains were also tested. All viruses, but A/swine/
Parma/1/97, were cultured on MDCK cells propagated in MEM
(GIBCO), supplemented with 10% fetal bovine serum (GIBCO),
50 μg/ml of penicillin (Gibco), 100 μg/ml of streptomycin (Gibco)
and of L-glutamine (2 mM) (EuroClone). The A/swine/PR/1/97
isolate was analogously grown on a different, more permissive cell line
(NSK-newborn swine kidney), kindly provided by the Istituto Zoopro-
ﬁlattico di Brescia. The cells were infected with each strain at 80%
conﬂuence, after addition to themediumof 1 μg/ml of trypsin. After the
infection, the cells were incubated at 35 °C, in 5% CO2 atmosphere.
Immunoﬂuorescence assays
Seven hours after infection, the MDCK cells were trypsinized,
washed twice in PBS and spotted on a slide by cytocentrifugation(2×105 cells in each spot). The cells were then ﬁxed and permeabi-
lized by cold methanol/acetone (−20 °C) for 10 min at room
temperature. After three washes in PBS, the cells were incubated for
30 min at 37 °C with each one of the HMabs (10 μg/mL). The cells
were then washed again in PBS and incubated for 30 min at 37 °C
with a ﬂuoresceinated anti-human Fab monoclonal diluted in Evans
Blue. Uninfected cells were used as control. Commercially available
anti-NP protein mouse monoclonal (Anti-inﬂuenza A group, Argene,
cod 11-030) was used as an infection control and as negative control
e509Fab was used on infected cells. The same protocol was used to
stain HEK 293T cells 48 h after transfection, but Hoechst (SIGMA)
was used for counterstaining. M145 Monoclonal Anti-Human
Inﬂuenza A (clone C179, Takara) directed against a conformational
epitope of the viral hemagglutinin was used as positive control in
transfection experiments.
Transfection of 293T cells with A/Puerto Rico/8/1934, A/South
Carolina/1/18 and A/Milan/UHSR1/2009 strain hemagglutinin genes
The full-length HA gene of A/Puerto Rico/8/1934 was ampliﬁed
with the above-described protocol and directly cloned into the
pcDNA3.1 expression vector (Invitrogen). In particular, the HA gene
was ampliﬁed by using the following pair of primers APR834 CAC CAT
GAA GGC AAA CCT ACT GGT CCT GTT ATG TG and APR834_as TCA GAT
GCA TAT TCT GCA CTG CAA AGA TCC ATT AGA and directly cloned
followingmanufacturer's instructions. Both the A/Milan/UHSR1/2009
and the A/South Carolina/1/18 HA genes were artiﬁcially synthesized
(Geneart AG, Germany) ﬂanking the full-length HA sequence with the
recognition sites of Hind III and AgeI restriction enzymes at 5′ and 3′
extremities, respectively. Each artiﬁcially synthesized HA gene was
subcloned from the shuttle vector supplied by the manufacturer
(Geneart, AG, Germany) into the pcDNA3.1 expression vector after
digestion with Hind III and AgeI enzymes. HEK 293T cells were
transfected with lipofectamine 2000 reagent (Invitrogen) with the
recombinant HA expression vectors following the manufacturer's
instructions. Forty-eight hours after transfection, cells were collected,
washed twice with PBS and spotted on a slide by cytocentrifugation.
Immunoﬂuorescence was performed as described above.
Western blot
A Western blot assay was performed on lysates obtained from
HEK293T cells transfected or mock transfected with A/Milan/UHSR1/
2009 (S-OIV) HA expression vector. Ten micrograms of lysates
obtained by mechanical homogenization in NativePAGE™ Sample
Buffer (Invitrogen), were loaded on a 10% polyacrilamide gel. After
running, samples were transferred on a nitrocellulose membrane
(Hybond-ECL; Amersham Bioscience) overnight at 30 V and 90 mA.
The membrane was then blocked with PBS–milk (5%) for 1 h and then
washed three times with PBS–Tween20 (0.1%). Each HMab (5 μg/ml)
was then added together with the serum from a convalescent patient
(obtained 30 days after infection) and a commercially available
monoclonal antibody as positive controls (Anti-H1, GeneTex,
GTX28262). All antibodies were incubated for 1 h at room tempera-
ture. After washing with PBS–Tween 20 (0.1%), secondary antibodies
were added for 1 h and after an additional washing step, the substrate
solution was added (SuperSignal® West Pico Chemiluminescent
Substrate, PIERCE) and incubated for 2 min.
Virus neutralization assays
Fluorescence inhibition assay
Each viral isolate was titrated by the limiting dilution method, and
the viral titer calculated by the Reed-Muench formula. 100 TCID50 of
each isolate were preincubated 1 h at 37 °C with scalar concentrations
of each human Fab (from 0.125 to 20 μg/mL). 250 μL of each pre-
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at 37 °C (5% CO2). The cells were then washed twice in PBS; 1.5 mL of
serum-free medium with trypsin (1 μg/mL) was added, and the cells
were incubated 6 h at 37 °C. The cells were then washed again with
PBS, ﬁxed and permeabilized with cold methanol/acetone. The
number of infected cells on each slide was then revealed using the
anti-NPmonoclonal antibodies, as above. An infection control without
antibody was added, as well as a negative control with e509 anti-
HCV/E2 monoclonal Fab. Each neutralization assay was performed in
triplicate and repeated in three different sessions. The neutralization
activity for each Fab concentration was expressed as the percentage
reduction of ﬂuorescent nuclei compared with the nuclei counted in
the infection control. The neutralization curves were then ﬁtted by
nonlinear regression with the GraphPad Prism software, allowing IC50
calculation (HMab concentration giving 50% neutralization).
Plaque inhibition assay
Each viral isolate was titrated by the limiting dilution method, and
the viral titer was calculated either as plaque forming units (PFU) on
six-well ﬂat-bottomed plates either as TCID50. 100 TCID50 of each
isolate were preincubated 1 h at 37 °C with different concentrations of
the human Fabs. The same controls used in IF assay were also used in
the plaque reduction assay. One milliliter of each neutralization mix
was added on MDCK monolayer and the infection was performed 1 h
at 35 °C in presence of 5% CO2. After the adsorption, the medium was
removed and the monolayer washed twice with sterile PBS. Two
milliliters of MEM-agarose 0.8% supplemented with antibiotics
(penicillin (50 μg/ml) (GIBCO), streptomycin (100 μg/ml) (GIBCO)
and of L-glutamine (2 mM)) and trypsin (1 μg/ml) were gently added
on each well, and the plates were incubated 48 h at 34 °C in presence
of 5% CO2. After 48 h the agarose medium was removed from each
well and 1 ml of 70% methanol-crystal violet 1% was added to each
well at room temperature. Finally, the wells were washed with tap
water and dried to allow the count of PFU. The neutralization was
determined counting the PFU reduction in presence of antibodies, in
comparison with PFU observed in the infection control.
EID50 (embryonated infectious dose) reduction assay for H5N1
inﬂuenza strains
Serial 10-fold dilutions (10−3 to 10−8) of Highly Pathogenic Avian
Inﬂuenza (HPAI) H5N1 viruses (A/chicken/Egypt/A6/2008 and A/
turkey/Turkey/1/2005) were prepared in PBS and each dilution was
mixedwith equal volume of HMAbs PN-SIA28 or PN-SIA49 (50 μg/ml)
or negative control (PBS). After incubation for 1 h at 37 °C, themixture
was inoculated into the allantoic cavities of 10-day-old embryonated
chicken eggs (ﬁve eggs for each viral dilution).
After 72 h of incubation at 37 °C, the eggs were checked for vitality,
chilled and allantoicﬂuidswere tested individually for HA activity. The
EID50 per 100 μl was calculated using the method of Reed-Muench.
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